Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years and \<70 years of age~* Diagnosis of hepatitis C~* Assessment of viral load prior to treatment (mandatory for genotype 1 only)~* Liver biopsy~* Co-morbidities data~* Use of interferon (pegylated or conventional) and ribavirin to treat hepatitis C infection genotype 2 and 3 and pegylated interferon plus ribavirin to treat hepatitis C infection genotype 1~* Above mentioned treatment started between 01-Sep-2007 and 31-Aug-2008~Exclusion Criteria:~* Co-infection with human immunodeficiency virus~* Co-infection with hepatitis B virus~* Presence of hepatocarcinoma~* Patients submitted to hemodialysis~* Organ transplant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Conventional Interferon Plus Ribavirin (Type: None): Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
- Peginterferon Alfa-2a Plus Ribavirin (Type: None): Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
- Peginterferon Alfa-2b Plus Ribavirin (Type: None): Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).

Based on this trial design, predict the completion outcome and termination type (if applicable).